Precision Oncology Conferences

As off-target toxicities plague many broad-spectrum oncology therapeutics, novel drugs that enable more precise targeting hold much promise in shaping the future of oncology drug development. As such, our goal is to create a platform for information sharing and relationship building to advance more precise and less toxic drugs to more patients, faster.

0

Transforming Patient Outcomes by Developing More Targeted & Safer Oncology Therapeutics

Combining industry KOLs, pioneering biopharma, leading academics and world-leading solution providers, our conferences are designed to deliver industry leading insights and connections to accelerate the development of more effective cancer treatments for targeted patient populations. Our portfolio of events spans the entire oncology sector to support the right drugs making it to the right patients.

Conference

8th Targeted Radiopharmaceuticals Summit EU

December 2026

Advancing Radioligand Candidates to Commercialisation

Precision Oncology

Conference

15th Tumour Models London Summit

December 2026

Engineering Your Next Generation Tumour Models to Maximise Clinical Success

Precision Oncology

Conference

Peptide-based Therapeutics Summit Europe

December 2026

Turbocharging Peptide Discoveries to Efficacious & Accessible Patient Therapies

Precision Oncology

Conference

2nd T-Cell Engager Therapeutics Summit Europe

December 2026

Optimise Targeting, Reduce On-Target Off-Tumour Toxicities & Accelerate Immunotherapies

Precision Oncology

View and search all of our conferences.

View All Conferences

Accelerating the Development of More Efficacious Precision Oncology Therapeutics

Testimonials

“I’m looking forward to attending and presenting at the World Clinical Biomarkers & CDx Summit. This is a key meeting for researchers, biomarker developers and Pharma to connect and shape the future of Precision Medicine.”

Amy Gorman

Director, Global Commercial Strategy, Precision Medicine, Janssen

“This conference has been very insightful in the past as the field of CDx is still advancing and we can learn from each other’s experiences.”

Silva Krause

Senior Director, Clinical Biomarkers, Vertex Pharmaceuticals

“Very rewarding. Resulted in several big pharma collaborations.”

Co-Founder & CEO, Aracari Biosciences

“Really enjoyed the conference. Great integration with speakers and delegates. The small size made it easier to make connections. Overall, the quality of the speakers and delegates was very high. I would definitely recommend it and hope to return next year.”

Group Lead, Gamma Delta Therapeutics

What to Expect at Hanson Wade Conferences?